Eckerström, Marie
Nilsson, Staffan
Zetterberg, Henrik
Blennow, Kaj
Grahn, Anna
Funding for this research was provided by:
Vetenskapsrådet (#2018-02532, #2017-00915)
European Research Council (#681712)
Swedish government and the County Councils, the ALF agreement (#ALFGBG-720931, #ALFGBG-715986, ALFGBG-588341)
Alzheimer's Drug Discovery Foundation (#201809-2016682)
UK Dementia Research Institute
European Commission (No 860197)
Swedish Alzheimer foundation (#AF-742881)
Hjärnfonden (#FO2017-0243)
Torsten Söderberg Professorship in Medicine ate the Royal Swedish Academy of Sciences
Gothenburg University Library
Article History
Received: 14 April 2020
Accepted: 1 December 2020
First Online: 28 December 2020
Competing interests
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors declare that they have no conflict of interest.